• Je něco špatně v tomto záznamu ?

Clinical outcomes of pelvic bone marrow sparing radiotherapy for cervical cancer: A systematic review and meta-analysis of randomised controlled trials

M. Miszczyk, T. Wu, K. Kuna, M. Stankiewicz, E. Staniewska, Z. Nowicka, Z. Chen, LK. Mell, J. Widder, M. Schmidt, R. Tarnawski, P. Rajwa, SF. Shariat, P. Zhou

. 2024 ; 47 (-) : 100801. [pub] 20240531

Status neindexováno Jazyk angličtina Země Irsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018310

BACKGROUND: Concurrent chemoradiotherapy (CRT) is the standard treatment for locally advanced cervical cancer. We investigated how additional bone marrow sparing (BMS) affects the clinical outcomes. METHODS: We queried MEDLINE, Embase, Web of Science Core Collection, Google Scholar, Sinomed, CNKI, and Wanfang databases for articles published in English or Chinese between 2010/01/01 and 2023/10/31. Full-text manuscripts of prospective, randomised trials on BMS in cervical cancer patients treated with definitive or postoperative CRT were included. Risk of bias (RoB) was assessed using Cochrane Collaboration's RoB tool. Random-effects models were used for the meta-analysis. RESULTS: A total of 17 trials encompassing 1297 patients were included. The majority were single-centre trials (n = 1268) performed in China (n = 1128). Most trials used CT-based anatomical BMS (n = 1076). There was a comparable representation of trials in the definitive (n = 655) and postoperative (n = 582) settings, and the remaining trials included both.Twelve studies reported data on G ≥ 3 (n = 782) and G ≥ 2 (n = 754) haematologic adverse events. Both G ≥ 3 (OR 0.39; 95 % CI 0.28-0.55; p < 0.001) and G ≥ 2 (OR 0.29; 95 % CI 0.18-0.46; p < 0.001) toxicity were significantly lowered, favouring BMS. Seven studies (n = 635) reported data on chemotherapy interruptions, defined as receiving less than five cycles of cisplatin, which were significantly less frequent in patients treated with BMS (OR 0.44; 95 % CI 0.24-0.81; p = 0.016). There was no evidence of increased gastrointestinal or genitourinary toxicity.There were no signs of significant heterogeneity. Four studies were assessed as high RoB; sensitivity analyses excluding these provided comparable results for main outcomes. The main limitations include heterogeneity in BMS methodology between studies, low representation of populations most affected by cervical cancer, and insufficient data to assess survival outcomes. CONCLUSIONS: The addition of BMS to definitive CRT in cervical cancer patients decreases hematologic toxicity and the frequency of interruptions in concurrent chemotherapy. However, data are insufficient to verify the impact on survival and disease control.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018310
003      
CZ-PrNML
005      
20241016081837.0
007      
ta
008      
241008e20240531ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ctro.2024.100801 $2 doi
035    __
$a (PubMed)38946805
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Miszczyk, Marcin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Collegium Medicum - Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland
245    10
$a Clinical outcomes of pelvic bone marrow sparing radiotherapy for cervical cancer: A systematic review and meta-analysis of randomised controlled trials / $c M. Miszczyk, T. Wu, K. Kuna, M. Stankiewicz, E. Staniewska, Z. Nowicka, Z. Chen, LK. Mell, J. Widder, M. Schmidt, R. Tarnawski, P. Rajwa, SF. Shariat, P. Zhou
520    9_
$a BACKGROUND: Concurrent chemoradiotherapy (CRT) is the standard treatment for locally advanced cervical cancer. We investigated how additional bone marrow sparing (BMS) affects the clinical outcomes. METHODS: We queried MEDLINE, Embase, Web of Science Core Collection, Google Scholar, Sinomed, CNKI, and Wanfang databases for articles published in English or Chinese between 2010/01/01 and 2023/10/31. Full-text manuscripts of prospective, randomised trials on BMS in cervical cancer patients treated with definitive or postoperative CRT were included. Risk of bias (RoB) was assessed using Cochrane Collaboration's RoB tool. Random-effects models were used for the meta-analysis. RESULTS: A total of 17 trials encompassing 1297 patients were included. The majority were single-centre trials (n = 1268) performed in China (n = 1128). Most trials used CT-based anatomical BMS (n = 1076). There was a comparable representation of trials in the definitive (n = 655) and postoperative (n = 582) settings, and the remaining trials included both.Twelve studies reported data on G ≥ 3 (n = 782) and G ≥ 2 (n = 754) haematologic adverse events. Both G ≥ 3 (OR 0.39; 95 % CI 0.28-0.55; p < 0.001) and G ≥ 2 (OR 0.29; 95 % CI 0.18-0.46; p < 0.001) toxicity were significantly lowered, favouring BMS. Seven studies (n = 635) reported data on chemotherapy interruptions, defined as receiving less than five cycles of cisplatin, which were significantly less frequent in patients treated with BMS (OR 0.44; 95 % CI 0.24-0.81; p = 0.016). There was no evidence of increased gastrointestinal or genitourinary toxicity.There were no signs of significant heterogeneity. Four studies were assessed as high RoB; sensitivity analyses excluding these provided comparable results for main outcomes. The main limitations include heterogeneity in BMS methodology between studies, low representation of populations most affected by cervical cancer, and insufficient data to assess survival outcomes. CONCLUSIONS: The addition of BMS to definitive CRT in cervical cancer patients decreases hematologic toxicity and the frequency of interruptions in concurrent chemotherapy. However, data are insufficient to verify the impact on survival and disease control.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Wu, Tao $u Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, China
700    1_
$a Kuna, Kasper $u Department of Biostatistics and Translational Medicine, Medical University of Łódź, Łódź, Poland
700    1_
$a Stankiewicz, Magdalena $u Brachytherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland
700    1_
$a Staniewska, Emilia $u III Radiotherapy and Chemotherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland
700    1_
$a Nowicka, Zuzanna $u Department of Biostatistics and Translational Medicine, Medical University of Łódź, Łódź, Poland
700    1_
$a Chen, Ziqin $u Department of Hematological Oncology, No.1 Traditional Chinese Medicine Hospital in Changde, Changde, China
700    1_
$a Mell, Loren K $u Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA
700    1_
$a Widder, Joachim $u Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Schmidt, Maximilian $u Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Tarnawski, Rafał $u III Radiotherapy and Chemotherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland
700    1_
$a Rajwa, Paweł $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Division of Urology, Department of Special Surgery, University of Jordan, Amman, Jordan $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Research Centre for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran
700    1_
$a Zhou, Pixiao $u Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, China
773    0_
$w MED00213969 $t Clinical and translational radiation oncology $x 2405-6308 $g Roč. 47 (20240531), s. 100801
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38946805 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241008 $b ABA008
991    __
$a 20241016081832 $b ABA008
999    __
$a ok $b bmc $g 2196519 $s 1230261
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 47 $c - $d 100801 $e 20240531 $i 2405-6308 $m Clinical and translational radiation oncology $n Clin Transl Radiat Oncol $x MED00213969
LZP    __
$a Pubmed-20241008

Najít záznam

Citační ukazatele

Možnosti archivace